PNC Financial Services Group’s Eledon Pharmaceuticals ELDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$896 Sell
354
-748
-68% -$2.51K ﹤0.01% 5026
2026
Q2
$4.34K Buy
1,102
+165
+18% +$600 ﹤0.01% 4443
2026
Q1
$2.89K Buy
937
+932
+18,640% +$2.2K ﹤0.01% 4471
2025
Q4
$8 Sell
5
-4
-44% -$10 ﹤0.01% 5142
2025
Q3
$23 Buy
+9
New +$26 ﹤0.01% 5056

Other funds holding ELDN

PNC Financial Services Group's ELDN Position: Q3 2026 in Review

PNC Financial Services Group reduced its Eledon Pharmaceuticals (ELDN) stake by 68% in Q3 2026, selling an estimated $2.51K and leaving 354 shares worth $896. The position accounts for ﹤0.01% of the portfolio, ranked #5026.

PNC Financial Services Group first reported a position in ELDN in Q3 2025 and has held it in 5 quarters since. The position peaked at $4.34K in Q2 2026. 155 funds tracked by Wall St. Rank hold ELDN as of Q3 2026.

  • PNC Financial Services Group held 354 shares of Eledon Pharmaceuticals worth $896 as of Q3 2026.
  • PNC Financial Services Group sold 748 Eledon Pharmaceuticals shares in Q3 2026, an estimated $2.51K.
  • Eledon Pharmaceuticals made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #5026 holding.
  • PNC Financial Services Group first reported a position in Eledon Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • PNC Financial Services Group's Eledon Pharmaceuticals position peaked at $4.34K in Q2 2026.
  • 155 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.